Premise-Crossover Merger: Inside the $2B Push for a New Employer Health Model
Premise Health and Crossover Health are merging to create a nearly $2 billion company. The partners plan to scale advanced primary care — an integrated bundle of primary care, behavioral health, pharmacy services and care navigation — for large self-insured employers.
Is It Time to Change the Independent Dispute Resolution Process of the No Surprises Act?
The No Surprises Act protected patients from surprise bills, but its Independent Dispute Resolution process has become controversial as insurers accuse some providers of exploiting it at scale.
Medication Affordability Depends on Total Price Transparency
At a time when 98 million prescriptions are abandoned due to cost surprises, it’s critical that all four categories of prescription drug prices are available so consumers can determine how to obtain needed medications at the lowest cost.
2026 Is the Year of the Doctor-Patient Relationship
When paired with the expertise of health care providers, who serve as guides, partners in care, and healers, we have the critical elements in the formula for providing the patient with quality, personalized care, not merely on an episodic basis, but as the foundation of improved whole person care to take them through their life’s journeys.
Clinical Trial Holds Cast Doubt on Approval Chances of Regenxbio Gene Therapy for Rare Disease
Tests of two Regenxbio gene therapies have been placed under an FDA clinical hold after a patient in one of the studies developed cancer. Our recap of recent regulatory news also includes one clinical hold removed, several complete response letters, and drug approvals in the U.S. and Europe.